JPH0458451B2 - - Google Patents
Info
- Publication number
- JPH0458451B2 JPH0458451B2 JP59054542A JP5454284A JPH0458451B2 JP H0458451 B2 JPH0458451 B2 JP H0458451B2 JP 59054542 A JP59054542 A JP 59054542A JP 5454284 A JP5454284 A JP 5454284A JP H0458451 B2 JPH0458451 B2 JP H0458451B2
- Authority
- JP
- Japan
- Prior art keywords
- kallidinogenase
- agent
- sodium citrate
- improving
- cerebral metabolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000001399 Kallikrein Human genes 0.000 claims description 40
- 108060005987 Kallikrein Proteins 0.000 claims description 40
- 229960003709 kallidinogenase Drugs 0.000 claims description 40
- 239000001509 sodium citrate Substances 0.000 claims description 15
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000002485 urinary effect Effects 0.000 claims description 11
- 230000002490 cerebral effect Effects 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 206010001605 Alcohol poisoning Diseases 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 208000026680 Metabolic Brain disease Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- OMRXVBREYFZQHU-UHFFFAOYSA-N 2,4-dichloro-1,3,5-triazine Chemical compound ClC1=NC=NC(Cl)=N1 OMRXVBREYFZQHU-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
- 108010003195 Kallidin Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- -1 Polyethylene Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59054542A JPS60199827A (ja) | 1984-03-23 | 1984-03-23 | 人尿性カリジノゲナーゼを有効成分とする脳代謝障害改善剤 |
| JP3305565A JPH0570368A (ja) | 1984-03-23 | 1991-10-25 | 末梢血管障害治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59054542A JPS60199827A (ja) | 1984-03-23 | 1984-03-23 | 人尿性カリジノゲナーゼを有効成分とする脳代謝障害改善剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3305565A Division JPH0570368A (ja) | 1984-03-23 | 1991-10-25 | 末梢血管障害治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60199827A JPS60199827A (ja) | 1985-10-09 |
| JPH0458451B2 true JPH0458451B2 (de) | 1992-09-17 |
Family
ID=12973558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59054542A Granted JPS60199827A (ja) | 1984-03-23 | 1984-03-23 | 人尿性カリジノゲナーゼを有効成分とする脳代謝障害改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60199827A (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0771459B2 (ja) * | 1991-05-15 | 1995-08-02 | 三協食品工業株式会社 | 機能性食品素材とその製造方法 |
| JPH05163158A (ja) * | 1991-12-13 | 1993-06-29 | Sanwa Kagaku Kenkyusho Co Ltd | 人尿性キニノゲナーゼを有効成分とする皮膚潰瘍の予防及び治療剤 |
| EP0546533A2 (de) * | 1991-12-10 | 1993-06-16 | Sanwa Kagaku Kenkyusho Co., Ltd. | Medizinische Verwendung von Kininogenase |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59102392A (ja) * | 1982-12-02 | 1984-06-13 | Nippon Chem Res Kk | 熱安定性を有するヒト尿キニノゲナーゼ水溶液の製造法 |
-
1984
- 1984-03-23 JP JP59054542A patent/JPS60199827A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59102392A (ja) * | 1982-12-02 | 1984-06-13 | Nippon Chem Res Kk | 熱安定性を有するヒト尿キニノゲナーゼ水溶液の製造法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60199827A (ja) | 1985-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1254510A (en) | Fibronectin preparations | |
| US8580745B2 (en) | Composition for therapeutic and cosmetic botulinum toxin | |
| TWI242443B (en) | Activated protein C formulations | |
| US5081156A (en) | Sustained-release preparation | |
| JP2021059549A (ja) | プラミノーゲンを含む医薬組成物及びその使用 | |
| JPH06510031A (ja) | ヒトタンパク質を含有する注入用又は注射用医薬製剤の製造方法 | |
| JPS6156134A (ja) | コラ−ゲン性医薬組成物 | |
| US5024844A (en) | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient | |
| EP0138216A2 (de) | IFN-Präparat mit verzögerter Abgabe für parentale Verabreichung | |
| US20190367636A1 (en) | Novel stable formulation for fxia antibodies | |
| JP6880058B2 (ja) | シクロデキストリン−パノビノスタット付加物 | |
| EA008438B1 (ru) | Парентеральные композиции пептида для лечения системной красной волчанки | |
| JPH0458451B2 (de) | ||
| KR100725076B1 (ko) | Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물 함유 용액 및 제제 | |
| KR100807650B1 (ko) | Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법 | |
| JP2688603B2 (ja) | 血栓溶解剤 | |
| RU2112542C1 (ru) | Препарат для лечения патологических состояний соединительной ткани | |
| JPH07502734A (ja) | 血液損失を減少する方法および組成物 | |
| JPS62153224A (ja) | プラスミノゲン製剤 | |
| JPH08782B2 (ja) | 抗炎症剤 | |
| US20030007959A1 (en) | Oral methods of treatment | |
| JPH0296535A (ja) | 骨髄機能障害性貧血治療剤 | |
| JPH01268645A (ja) | シュワルツマン反応抑制剤 | |
| RU2058788C1 (ru) | Способ получения препарата инсулина для перорального применения | |
| US5888964A (en) | Method for increasing placental blood flow |